Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Life Sciences	$2.31 +4.5%	$1.52	$1.03 ▼ $2.57	$462.78M	1.22	1.60 million shs	2.93 million shs
BHST BioHarvest Sciences	$6.35 +1.6%	$6.17	$6.25 ▼ $7.38	$104.30M	0.8	17,233 shs	9,949 shs
MGTX MeiraGTx	$5.10 +0.2%	$5.91	$3.85 ▼ $8.75	$409.06M	1.3	363,981 shs	330,181 shs
ORKA Oruka Therapeutics	$11.47 +0.3%	$9.75	$5.49 ▼ $31.13	$428.33M	0.25	225,159 shs	123,010 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Life Sciences	+4.52%	+20.94%	+58.22%	+40.00%	+39.16%
BHST BioHarvest Sciences	+1.60%	+4.10%	+1.44%	+22.35%	+634,999,900.00%
MGTX MeiraGTx	+0.20%	-3.77%	-25.11%	-26.93%	-0.78%
ORKA Oruka Therapeutics	+0.26%	+8.41%	+11.58%	+19.98%	+1,146,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI Atai Life Sciences	2.1722 of 5 stars	3.7	1.0	0.0	0.0	2.0	2.5	0.6
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	4.4547 of 5 stars	3.5	2.0	0.0	4.8	2.0	2.5	1.9
ORKA Oruka Therapeutics	2.615 of 5 stars	3.6	0.0	0.0	0.0	2.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Life Sciences	3.33	Buy	$8.67	275.18% Upside
BHST BioHarvest Sciences	3.00	Buy	$13.67	115.22% Upside
MGTX MeiraGTx	3.00	Buy	$24.00	370.59% Upside
ORKA Oruka Therapeutics	3.20	Buy	$40.38	252.01% Upside

Current Analyst Ratings Breakdown

Latest BHST, ATAI, ORKA, and MGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/22/2025	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$44.00
5/20/2025	ATAI Atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI Atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/15/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$40.00 ➝ $40.00
5/14/2025	MGTX MeiraGTx	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $35.00
5/13/2025	ATAI Atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/5/2025	BHST BioHarvest Sciences	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/8/2025	BHST BioHarvest Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
3/19/2025	ATAI Atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/17/2025	MGTX MeiraGTx	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$11.00 ➝ $13.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Life Sciences	$1.86M	248.41	N/A	N/A	$1.47 per share	1.57
BHST BioHarvest Sciences	$27.70M	3.76	N/A	N/A	($1.08) per share	-5.88
MGTX MeiraGTx	$34.51M	11.88	N/A	N/A	$2.17 per share	2.35
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Life Sciences	-$40.22M	-$0.91	N/A	N/A	N/A	N/A	-65.75%	-52.71%	8/12/2025 (Estimated)
BHST BioHarvest Sciences	-$12.56M	-$0.50	N/A	N/A	N/A	-76.65%	N/A	-85.16%	5/29/2025 (Estimated)
MGTX MeiraGTx	-$84.03M	-$2.32	N/A	13.42	0.37	-633.05%	-146.38%	-53.05%	8/11/2025 (Estimated)
ORKA Oruka Therapeutics	-$5.34M	-$4.51	N/A	N/A	N/A	N/A	-24.96%	-21.22%	8/7/2025 (Estimated)

Latest BHST, ATAI, ORKA, and MGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q1 2025	BHST BioHarvest Sciences	-$0.15	-$0.13	+$0.02	-$0.13	$7.80 million	$7.64 million
5/15/2025	Q1 2025	BHST BioHarvest Sciences	-$0.15	-$0.13	+$0.02	-$0.13	$8.93 million	$7.64 million
5/14/2025	Q1 2025	ATAI Atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/14/2025	Q1 2025	ORKA Oruka Therapeutics	-$0.57	-$0.40	+$0.17	-$0.40	N/A	N/A
5/13/2025	Q1 2025	MGTX MeiraGTx	-$0.38	-$0.51	-$0.13	-$0.51	$4.44 million	$1.93 million
3/31/2025	Q4 2024	BHST BioHarvest Sciences	-$0.12	-$0.17	-$0.05	-$0.17	$7.24 million	$7.17 million
3/17/2025	Q4 2024	ATAI Atai Life Sciences	-$0.14	-$0.24	-$0.10	-$0.24	$0.30 million	($0.01) million
3/13/2025	Q4 2024	MGTX MeiraGTx	-$0.48	-$0.50	-$0.02	-$0.50	$1.50 million	$21.39 million
3/6/2025	Q4 2024	ORKA Oruka Therapeutics	-$0.68	-$0.49	+$0.19	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Life Sciences	N/A	N/A	N/A	N/A	N/A
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Life Sciences	0.14	5.81	5.81
BHST BioHarvest Sciences	N/A	0.80	0.48
MGTX MeiraGTx	0.86	2.34	2.34
ORKA Oruka Therapeutics	N/A	22.89	22.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Life Sciences	28.41%
BHST BioHarvest Sciences	N/A
MGTX MeiraGTx	67.48%
ORKA Oruka Therapeutics	56.44%

Insider Ownership

Company	Insider Ownership
ATAI Atai Life Sciences	31.20%
BHST BioHarvest Sciences	N/A
MGTX MeiraGTx	7.50%
ORKA Oruka Therapeutics	22.67%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Life Sciences	80	200.34 million	115.45 million	Optionable
BHST BioHarvest Sciences	N/A	16.43 million	N/A	N/A
MGTX MeiraGTx	300	80.37 million	71.59 million	Optionable
ORKA Oruka Therapeutics	N/A	37.44 million	27.07 million	N/A

BHST, ATAI, ORKA, and MGTX Headlines

Recent News About These Companies

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $40.38 Average Price Target from Brokerages

May 29 at 1:27 AM | americanbankingnews.com

Jefferies Financial Group Inc. Makes New $6.79 Million Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

May 28 at 7:02 AM | marketbeat.com

H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial

May 27 at 4:12 PM | insidermonkey.com

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of "Buy" by Analysts

May 27 at 1:16 AM | marketbeat.com

58,332 Shares in Oruka Therapeutics, Inc. (NASDAQ:ORKA) Purchased by Toronto Dominion Bank

May 26 at 4:16 AM | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) Raised to Hold at StockNews.com

May 24, 2025 | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated by Analysts at BTIG Research

May 24, 2025 | marketbeat.com

Frazier Life Sciences Management L.P. Grows Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

May 23, 2025 | marketbeat.com

VR Adviser LLC Buys 200,000 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)

May 22, 2025 | marketbeat.com

Point72 Asset Management L.P. Cuts Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

May 22, 2025 | marketbeat.com

Oruka Therapeutics begins trial for psoriasis treatment

May 21, 2025 | uk.investing.com

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

May 21, 2025 | globenewswire.com

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

May 20, 2025 | globenewswire.com

Wedbush Predicts Weaker Earnings for Oruka Therapeutics

May 20, 2025 | americanbankingnews.com

Wedbush Forecasts Reduced Earnings for Oruka Therapeutics

May 20, 2025 | marketbeat.com

Contrasting Oruka Therapeutics (NASDAQ:ORKA) & Trinity Biotech (NASDAQ:TRIB)

May 19, 2025 | americanbankingnews.com

RTW Investments LP Boosts Stock Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

May 18, 2025 | marketbeat.com

Polar Capital Holdings Plc Buys New Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

May 18, 2025 | marketbeat.com

Janus Henderson Group PLC Boosts Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

May 18, 2025 | marketbeat.com

TD Cowen Remains a Buy on Oruka Therapeutics (ORKA)

May 17, 2025 | theglobeandmail.com

Wedbush Sticks to Its Buy Rating for Oruka Therapeutics (ORKA)

May 17, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHST, ATAI, ORKA, and MGTX Company Descriptions

Atai Life Sciences NASDAQ:ATAI

$2.31 +0.10 (+4.52%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$2.34 +0.02 (+1.08%)

As of 05/28/2025 07:57 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

BioHarvest Sciences NASDAQ:BHST

$6.35 +0.10 (+1.60%)

As of 05/28/2025 03:53 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

MeiraGTx NASDAQ:MGTX

$5.10 +0.01 (+0.20%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$5.11 +0.01 (+0.20%)

As of 05/28/2025 04:04 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Oruka Therapeutics NASDAQ:ORKA

$11.47 +0.03 (+0.26%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$11.48 +0.01 (+0.13%)

As of 05/28/2025 05:27 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time